Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Magnevist
Drug ID BADD_D01345
Description A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)
Indications and Usage For use with magnetic resonance imaging (MRI) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues as well as lesions with abnormal vascularity in the head and neck. Also used to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart).
Marketing Status Prescription
ATC Code V08CA01
DrugBank ID DB00789
KEGG ID D01707
MeSH ID D019786
PubChem ID 55466
TTD Drug ID D0RQ2W
NDC Product Code Not Available
Synonyms Gadolinium DTPA | DTPA, Gadolinium | Gadolinium Diethylenetriaminepenta-acetic Acid | Diethylenetriaminepenta-acetic Acid, Gadolinium | Gadolinium Diethylenetriaminepenta acetic Acid | Gadopentetic Acid | Gd-DTPA | Gd DTPA | Gadolinium DTPA Disodium Salt | Magnograf | Magnograf Enteral | Gadopentetate Dimeglumine | Dimeglumine, Gadopentetate | Gadolinium DTPA Dimeglumine Salt | Gadolinium DTPA Dimeglumine | Dimeglumine, Gadolinium DTPA | Magnevist | Magnevist Enteral
Chemical Information
Molecular Formula C28H54GdN5O20
CAS Registry Number 80529-93-7
SMILES CNCC(C(C(C(CO)O)O)O)O.CNCC(C(C(C(CO)O)O)O)O.C(CN(CC(=O)O)CC(=O)[O-])N(CCN(CC(=O) O)CC(=O)[O-])CC(=O)[O-].[Gd+3]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Hypothermia12.05.03.001; 08.05.01.003--
Immune system disorder10.02.01.001--Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.001--Not Available
Injection site extravasation12.07.03.002; 08.02.03.002--Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.005--Not Available
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site irritation12.07.03.027; 08.02.03.027--Not Available
Injection site necrosis08.02.03.020; 12.07.03.020--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site paraesthesia17.02.06.029; 12.07.03.049; 08.02.03.049--Not Available
Injection site phlebitis12.07.03.012; 08.02.03.011; 24.05.03.003--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Injection site thrombosis24.01.01.023; 08.02.03.028; 12.07.03.028--Not Available
Injection site warmth12.07.03.036; 08.02.03.036--Not Available
Lacrimation increased06.08.02.004--
Laryngeal oedema10.01.05.003; 23.04.01.005; 22.04.02.001--
Laryngeal pain22.02.05.036--
Laryngospasm22.04.02.002--
Loss of consciousness17.02.04.004--Not Available
Lymphangitis24.09.02.001; 11.01.15.001; 01.09.01.005--Not Available
Malaise08.01.01.003--
Micturition urgency20.02.02.006--
Migraine24.03.05.003; 17.14.02.001--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages